Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2,EBioMedicine

当前位置： X-MOL 学术 › EBioMedicine › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
EBioMedicine ( IF 11.1 ) Pub Date : 2021-08-12 , DOI: 10.1016/j.ebiom.2021.103523
Sebastian Havervall ₁ , Ulrika Marking ₁ , Nina Greilert-Norin ₁ , Henry Ng ₂ , Max Gordon ₁ , Ann-Christin Salomonsson ₁ , Cecilia Hellström ₃ , Elisa Pin ₃ , Kim Blom ₄ , Sara Mangsbo ₅ , Mia Phillipson ₆ , Jonas Klingström ₇ , Sophia Hober ₃ , Peter Nilsson ₃ , Mikael Åberg ₈ , Charlotte Thålin ₁

Affiliation

Background

Recent reports demonstrate robust serological responses to a single dose of messenger RNA (mRNA) vaccines in individuals previously infected with SARS-CoV-2. Data on immune responses following a single-dose adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein (ChAdOx1 nCoV-19) in individuals with previous SARS-CoV-2 infection are however limited, and current guidelines recommend a two-dose regimen regardless of preexisting immunity.

Methods

We compared RBD-specific IgG and RBD-ACE2 blocking antibodies against SARS-CoV-2 wild type and variants of concern following two doses of the mRNA vaccine BNT162b2 in SARS-CoV-2 naïve healthcare workers (n=65) and a single dose of the adenovector vaccine ChAdOx1 nCoV-19 in 82 healthcare workers more than (n=45) and less than (n=37) 11 months post mild SARS-CoV-2 infection at time of vaccination.

Findings

The post-vaccine levels of RBD-specific IgG and neutralizing antibodies against the SARS-CoV-2 wild type and variants of concern including Delta lineage 1.617.2 were similar or higher in participants receiving a single dose of ChAdOx1 nCoV-19 vaccine post SARS-CoV-2 infection (both more than and less than 11 months post infection) compared to SARS-CoV-2 naïve participants who received two doses of BNT162b2 vaccine.

Interpretation

Our data support that a single dose ChAdOx1 nCoV-19 vaccine that is administered up to at least 11 months post SARS-CoV-2 infection serves as an effective immune booster. This provides a possible rationale for a single-dose vaccine regimen.

Funding

A full list of funding bodies that contributed to this study can be found in the Acknowledgements section

中文翻译：

先前感染 SARS-CoV-2 的医护人员接种单剂 ChAdOx1 nCoV-19 疫苗后的抗体反应

背景

最近的报告表明，先前感染 SARS-CoV-2 的个体对单剂信使 RNA (mRNA) 疫苗产生了强烈的血清学反应。然而，关于在先前感染过 SARS-CoV-2 的个体中表达 SARS-CoV-2 刺突蛋白 (ChAdOx1 nCoV-19) 的单剂量腺病毒载体疫苗后免疫反应的数据有限，目前的指南推荐两剂无论先前存在的免疫力如何。

方法

我们比较了针对 SARS-CoV-2 野生型和关注变体的 RBD 特异性 IgG 和 RBD-ACE2 阻断抗体，在 SARS-CoV-2 天真医护人员（n = 65）和单剂注射两剂 mRNA 疫苗 BNT162b2 后在接种疫苗时，在轻度 SARS-CoV-2 感染后超过 (n=45) 和不到 (n=37) 11 个月的 82 名卫生保健工作者中检测了腺载体疫苗 ChAdOx1 nCoV-19。

发现

在 SARS 后接受单剂 ChAdOx1 nCoV-19 疫苗的参与者中，针对 SARS-CoV-2 野生型和关注变体（包括 Delta 谱系 1.617.2）的 RBD 特异性 IgG 和中和抗体的疫苗接种后水平相似或更高-CoV-2 感染（感染后超过 11 个月和不到 11 个月）与接受两剂 BNT162b2 疫苗的 SARS-CoV-2 初次参与者相比。